<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2019-6-1169-1178</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1793</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>Диагностическая ценность растворимых молекул адгезии и костимуляторных молекул иммунокомпетентных клеток у больных ишемической болезнью сердца</article-title><trans-title-group xml:lang="en"><trans-title>Diagnostic significance of soluble adhesion molecules and costimulatory molecules of immune cells in the patients with ischemic heart disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3397-136X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логаткина</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Logatkina</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Логаткина Анна Владимировна — аспирант кафедры внутренних болезней Медицинского института</p></bio><bio xml:lang="en"><p>Postgraduate Student, Department of Internal Medicine, Medical Institute</p></bio><email xlink:type="simple">Logatkina_a@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6548-083X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терехов</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Terekhov</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Терехов Игорь Владимирович — кандидат медицинских наук, доцент кафедры общей патологии Медицинского института</p><p>300012, Тула, ул. Смидович, 12, Тел.: 8 (906) 509-80-19</p></bio><bio xml:lang="en"><p>Terekhov Igor V. - PhD (Medicine), Associate Professor, Department of General Pathology, Medical Institute.</p><p>300012, Tula, Smidovich str., 12, Phone: 7 (906) 509-80-19</p></bio><email xlink:type="simple">trft@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2749-8366</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бондарь</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bondar</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бондарь Станислав Станиславович — аспирант кафедры внутренних болезней Медицинского института</p></bio><bio xml:lang="en"/><email xlink:type="simple">stos34@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7862-0937</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Никифоров</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Nikiforov</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Никифоров Виктор Сергеевич — доктор медицинских наук, профессор, профессор кафедры функциональной диагностики.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Department of Functional Diagnostics.</p><p>St. Petersburg</p></bio><email xlink:type="simple">viktor.nikiforov@szgmu.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУВО Тульский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tula State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Северо-Западный государственный медицинский университет имени И.И. Мечникова» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I. Mechnikov North-Western State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>12</day><month>01</month><year>2020</year></pub-date><volume>21</volume><issue>6</issue><fpage>1169</fpage><lpage>1178</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Логаткина А.В., Терехов И.В., Бондарь С.С., Никифоров В.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Логаткина А.В., Терехов И.В., Бондарь С.С., Никифоров В.С.</copyright-holder><copyright-holder xml:lang="en">Logatkina A.V., Terekhov I.V., Bondar S.S., Nikiforov V.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/1793">https://www.mimmun.ru/mimmun/article/view/1793</self-uri><abstract><p>Ишемическая болезнь сердца представляет важную медико-социальную проблему, что определяется высокой распространенностью заболевания, неуклонным прогрессирующим течением, занимающим лидирующее место в структуре смертности.</p><p>Учитывая важную роль в прогрессировании ИБС воспалительного процесса сосудистой стенки, поддерживающегося за счет активированных макрофагов, Т-лимфоцитов и NK-клеток, очевидно, что маркеры их активации могут играть определенную роль в оценке активности иммуновоспалительного процесса, а, следовательно, использоваться для прогнозирования состояния здоровья таких пациентов.</p><p>В соответствии с вышесказанным целью настоящего исследования являлось изучение информативности растворимых форм костимуляторнных молекул, а также молекул адгезии у пациентов со стенокардией напряжения и острым коронарным синдромом.</p><p>В ходе контролируемого клинического исследования обследовано 48 пациентов обоего пола с ИБС в возрасте от 55 до 70 лет, а также 15 практически здоровых лиц в возрасте 50-70 лет. Основная группа, которую составили пациенты с ИБС, была разделена на две подгруппы. В первую подгруппу включены 25 пациентов со стенокардией напряжения 2-3 функционального класса, во вторую подгруппу основной группы включены 23 пациента, поступившие в клинику с острым коронарным синдромом, сопровождавшимся подъемом сегмента ST на электрокардиограмме и оценкой по шкале GRACE от 125 до 140 баллов (средний возраст обследованных составил 68,5±5,0 лет).</p><p>В ходе исследования в сыворотке крови методом иммуноферментного анализа определяли концентрацию молекул адгезии sICAM-1, sVCAM-1, лейкоцитарного (L) и тромбоцитарного (P) селек-тинов, sCD28, sCD40, sCD40L, sCD80, sCD152, sFas, sFasL.</p><p>Проведенный анализ показал, что у пациентов со СН имеет место повышение уровня sCD152 на 77,8 (р = 0,026), sCD40 на 22,2% (р = 0,038), sVCAM-1 в 1,98 раза (р = 0,011). Также отмечено снижение уровня L- и P-селектинов на 51,6% (р = 0,029) и 29,0% (р = 0,04) соответственно, а также sСD80 на 77,1% (р = 0,026), sCD40L на 30,8% (р = 0,041), sFas на 54,4 (р = 0,038), sFasL на 32,5% (р = 0,043). В подгруппе ОКС, в сравнении с группой контроля, отмечалось повышение уровня sCD152 на 61,1% (р = 0,029), sCD40 на 29,6% (р = 0,041), sVCAM-1 в 3,16 раза (р = 0,001). На этом фоне имело место снижение концентрации L-селектина на 71,6% (р = 0,025), P-селектина на 32,1% (р = 0,043), sCD80 на 6,4% (р = 0,023), sCD28 на 48,1% (р = 0,038), sCD40 на 29,6% (р = 0,046), sCD40L на 28,2% (р = 0,045), sFas на 48,5% (р = 0,041), sFasL на 12,5% (р = 0,05). У пациентов с ОКС, в сравнении со СН, отмечено снижение экспрессии L-селектина на 41,3% (р = 0,033), sCD28 на 30,1% (р = 0,036), sFasL на 29,6% (р = 0,041), sFas на 12,5% (р = 0,06), при повышении уровня sVCAM-1 на 59,0% (р = 0,027).</p><p>У обследованных больных ИБС выявлен повышенный уровень sCD152, sCD40 и sVCAM-1, при снижении экспрессии L- и P-селектинов, sСD80, sCD40L, а также sFas и sFasL. На фоне ОКС отмечается дальнейшее снижение экспрессии L-селектина, sVCAM-1, sCD28, sFasL и sFas, а также наблюдается относительное повышение уровня FasL над уровнем Fas. Наиболее точными маркерами ОКС являются L-селектин, информативность которого составляет 91% при диагностическом значении 7,7 нг/мл (95% ДИ 78-98%), а также FasL с информативностью 93% (84-99%) при диагностическом значении 3,1 нг/мл. Выявленные характерные для ОКС изменения исследованных маркеров, в частности повышение уровня FasL и снижение CD28, указывают на возможную патогенетическую связь развития обострения ИБС с дисбалансом активности Т-регуляторных лимфоцитов и Т-хелперов 17, а также повышенной активацией процессов апоптоза эндотелиоцитов коронарных артерий.</p></abstract><trans-abstract xml:lang="en"><p>Ischemic heart disease (IHD) represents significant medical issues, due to high prevalence of the disorder, permanent progressive course, being a leading cause of mortality. With respect to important role of vascular wall inflammation in IHT sipported by the inflammatory macrophages, Т cells and NK cells, one should conclude that their activation markers may play certain role in evaluation of intensity of immune inflammation, and, therefore, they could be used for prediction of health consequences for the patients. Hence, the aim of this study was to assess diagnostic value of soluble co-stimulatory molecules, as well as adhesion molecules in the patients with effort angina and acute coronary syndrome. In the course of controlled clinical study, we have examined 48 patients with IHD, of both genders at the age of 55 to 70 years, as well as 15 healthy persons aged 50 to 70 лет. The main group of IHD patients was divided into 2 subgroups: the 1st subgroup included 25 cases with effort angina, functional class 2-3; the 2nd subgroup consisted of 23 patients admitted to the clinic with acute coronary syndrome with ST elevation on ECG, and GRACE score of 125 to 140 points. The mean age of the observed patients was 68.5±5.0 years old). In the course of the study, serum contents of adhesion molecules (sICAM-1, sVCAM-1, leukocyte (L) and platelet (P) selectins), like as sCD28, sCD40, sCD40L, sCD80, sCD152, sFas, sFasL were measured by means of immunoenzyme technique. The data analysis has shown an increase of sCD152 levels by 77.8% (р = 0.026); sCD40 elevated by 22.2% (р = 0.038), and sVCAM was increased 1.98-fold (р = 0.011) in the effort angina patients. Similarly, we revealed a decrease in L- and P-selectins, respectively, by 51.6% (р = 0.029), and 29.0 % (р = 0.04), as well as decrease of sСD80 by 77.1% (р = 0.026); sCD40L by 30.8% (р = 0.041), sFas by 54.4 (р = 0.038), sFasL на 32.5% (р = 0.043). In acute coronary syndrome, if compared to control group, an increase in sCD152 was found by 61.1% (р = 0.029); sCD40 by 29.6% (р = 0.041); sVCAM-1 was elevated 3.16-fold (р = 0.001), along with decreased concentrations of L-selectin by 71.6% (р = 0.025); P-selectin by на 32.1% (р = 0.043); sCD80 by 76.4% (р = 0.023); sCD28 by 48.1% (р = 0.038); sCD40 by 29.6% (р = 0.046); sCD40L by 28.2% (р = 0.045); sFas by 48.5% (р = 0.041); sFasL by 12.5% (р = 0.05). The patients with acute coronary syndrome, in comparison with effort angina, exhibited a diminished L-selectin expression by 41.3% (р = 0.033); sCD28 by 30.1% (р = 0.036); sFasL by 29.6% (р = 0.041); sFas by 12.5% (р = 0.06), whereas sVCAM-1 levels were increased by 59.0% (р = 0.027). The examined patients with IHD exhibited increased levels of serum sCD152, sCD40 and sVCAM-1, along with decreased expression of L- and P-selectins, sCD80, sCD40L, as well as sFas and sFasL. In presence of acute coronary syndrome, a more pronounced drop in L-selectin, sVCAM-1, sCD28, sFasL and sFas expression like as relative increase of FasL over Fas levels. L-selectin is the most precise marker of acute coronary syndrome, with informativity of 91% and diagnostic threshold of 7.7 ng/mL (95% CI, 78-98%), as well as FasL with informativity of 93% (84-99%) and diagnostic value of 3.1 ng/mL. The detected changes of the markers studied in acute coronary syndrome, in particular, increased FasL levels and diminished CD28 presume a possible pathogenetic relation between development of the IHD exacerbation and imbalance between T-regulatory lymphocytes and Th17 helper cells as well as pronounced apoptosis activation of endotheliocytes in coronary arteria.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>белки адгезии</kwd><kwd>сыворотка крови</kwd><kwd>костимуляторные факторы</kwd><kwd>иммунокомпетентные клетки</kwd><kwd>ишемическая болезнь сердца</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adherence proteins</kwd><kwd>blood serum</kwd><kwd>costimulatory factors</kwd><kwd>immune cells</kwd><kwd>ischemic heart disease</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Белокопытова И.С., Москалец О.В., Палеев Ф.Н., Зотова О.В. Диагностическое значение растворимых молекул адгезии sICAM-1 и sVCAM-1 при ишемической болезни сердца // Атеросклероз и дислипиде-мии, 2013. Т. 4, № 12. С. 62-65.</mixed-citation><mixed-citation xml:lang="en">Belokopytova I.S., Moskalets O.V., Paleev F.N., Zotova O.V. The diagnostic value of adhesive molecules sICAM -1 and sVCAM-1 in ischemic heart disease. Ateroskleroz i dislipidemii = Atherosclerosis and Dyslipidemia, 2013, Vol. 4, no. 12, pp. 62-65. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Логаткина А.В., Никифоров В.С., Бондарь С.С., Терехов И.В. Воспалительные цитокины и сигнальные системы мононуклеарных клеток периферической крови при ишемической болезни сердца // Клиническая медицина, 2017. Т. 95, № 3. С. 238-244.</mixed-citation><mixed-citation xml:lang="en">Logatkina A.V., Nikiforov V.S., Bondar S.S., Terekhov I.V. Proinflammatory cytokines and signaling pathways in peripheral blood mononuclear cells in patients with coronary artery disease. Klinicheskaya meditsina = Clinical Medicine (Russian Journal), 2017, Vol. 95, no. 3, pp. 238-244. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации по лечению стабильной ишемической болезни сердца. ЕSC 2013 // Российский кардиологический журнал, 2014. Т. 7, № 111. С. 7-79.</mixed-citation><mixed-citation xml:lang="en">The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology, 2014, Vol. 7, no. 111, pp. 7-79. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Стаценко М.Е., Деревянченко М.В. Роль системного воспаления в снижении эластичности магистральных артерий и прогрессировании эндотелиальной дисфункции у больных артериальной гипертензией в сочетании с ожирением, сахарным диабетом 2 типа // Российский кардиологический журнал, 2018. № 4. С. 32-36.</mixed-citation><mixed-citation xml:lang="en">Statsenko M.E., Derevyanchenko M.V. The role of systemic inflammation in decrease of elasticity of magistral arteries and in progression of endothelial dysfunction in patients with systemic hypertension, obesity and type 2 diabetes. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology, 2018, Vol. 4, no. 156, pp. 32-36. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Сысоев К.А. Морфофункциональные изменения эндотелия в патогенезе гипертонической болезни // Артериальная гипертензия, 2017. Т. 23, № 5. С. 447-456.</mixed-citation><mixed-citation xml:lang="en">Sysoev K.A. Morphofunctional alterations in endothelium in the pathogenesis of essential hypertension. Arterialnaya gipertenziya = Arterial Hypertension, 2017, Vol. 23, no. 5, pp. 447-456. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Хадарцев А.А., Логаткина А.В., Терехов И.В., Бондарь С.С. Динамика проявлений метаболического синдрома у пациентов с артериальной гипертензией на фоне комплексного использования низкоинтенсивной микроволновой терапии // Артериальная гипертензия, 2018. Т. 24, № 2. С. 206-216.</mixed-citation><mixed-citation xml:lang="en">Khadartsev A.A., Logatkina A.V, Terekhov I.V., Bondar S.S. Metabolic changes in hypertensive patients treated by low-intensity microwave therapy. Arterialnaya gipertenziya = Arterial Hypertension, 2018, Vol. 24, no. 2, pp. 206-216. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">An X., Jiang G., Cheng C., Lv Z., Liu Y., Wang F. Inhibition of platelets by clopidogrel suppressed Ang II-Induced vascular inflammation, oxidative stress, and remodeling. J. Am. Heart Assoc., 2018, Vol. 7, no. 21, e009600. doi: 10.1161/JAHA.118.009600.</mixed-citation><mixed-citation xml:lang="en">An X., Jiang G., Cheng C., Lv Z., Liu Y., Wang F. Inhibition of platelets by clopidogrel suppressed Ang II-Induced vascular inflammation, oxidative stress, and remodeling. J. Am. Heart Assoc., 2018, Vol. 7, no. 21, e009600. doi: 10.1161/JAHA.118.009600.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Atalar E., Ozmen F., Haznedaroglu I., Ai^il T., Ozer N., Ovun9 K., Aksoyek S., Kes S. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int. J. Cardiol., 2002, Vol. 84, no. 2-3, pp. 227-231.</mixed-citation><mixed-citation xml:lang="en">Atalar E., Ozmen F., Haznedaroglu I., Ai^il T., Ozer N., Ovun9 K., Aksoyek S., Kes S. Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int. J. Cardiol., 2002, Vol. 84, no. 2-3, pp. 227-231.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal S.S., Ismahil M.A., Goel M. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ. Heart Fail., 2017, Vol. 10, no. 3, e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688.</mixed-citation><mixed-citation xml:lang="en">Bansal S.S., Ismahil M.A., Goel M. Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure. Circ. Heart Fail., 2017, Vol. 10, no. 3, e003688. doi: 10.1161/CIRCHEARTFAILURE.116.003688.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng X., Liao Y.H., Ge H., Li B., Zhang J., Yuan J., Wang M., Liu Y., Guo Z., Chen J., Zhang J., Zhang L. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol., 2008, no. 127, pp. 89-97.</mixed-citation><mixed-citation xml:lang="en">Cheng X., Liao Y.H., Ge H., Li B., Zhang J., Yuan J., Wang M., Liu Y., Guo Z., Chen J., Zhang J., Zhang L. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol., 2008, no. 127, pp. 89-97.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Damle N.K., Klussman K., Leytze G., Ochs H.D., Aruffo A., Linsley P.S., Ledbetter J.A. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell. Immunol., 1993, Vol. 148, no. 1, pp. 144-156.</mixed-citation><mixed-citation xml:lang="en">Damle N.K., Klussman K., Leytze G., Ochs H.D., Aruffo A., Linsley P.S., Ledbetter J.A. Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7. Cell. Immunol., 1993, Vol. 148, no. 1, pp. 144-156.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Filippatos G., Ang E., Gidea C., Dincer E., Wang R., Uhal B.D. Fas induces apoptosis in human coronary artery endothelial cells in vitro. BMC Cell Biol., 2004, no. 5, p. 6.</mixed-citation><mixed-citation xml:lang="en">Filippatos G., Ang E., Gidea C., Dincer E., Wang R., Uhal B.D. Fas induces apoptosis in human coronary artery endothelial cells in vitro. BMC Cell Biol., 2004, no. 5, p. 6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Foks A.C., Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol., 2017, Vol. 174, no. 22, pp. 3940-3955.</mixed-citation><mixed-citation xml:lang="en">Foks A.C., Kuiper J. Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. Br. J. Pharmacol., 2017, Vol. 174, no. 22, pp. 3940-3955.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Haught W.H., Mansour M., Rothlein R., Kishimoto T.K., Mainolfi E.A., Hendricks J.B., Hendricks C., Mehta J.L. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am. Heart J., 1996, Vol. 132, no. 1, pp. 1-8.</mixed-citation><mixed-citation xml:lang="en">Haught W.H., Mansour M., Rothlein R., Kishimoto T.K., Mainolfi E.A., Hendricks J.B., Hendricks C., Mehta J.L. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. Am. Heart J., 1996, Vol. 132, no. 1, pp. 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen M.F., Hollander M.R., van Royen N., Horrevoets A.J., Lutgens E. CD40 in coronary artery disease: a matter of macrophages? Basic Res. Cardiol., 2016, Vol. 111, no. 4, p. 38.</mixed-citation><mixed-citation xml:lang="en">Jansen M.F., Hollander M.R., van Royen N., Horrevoets A.J., Lutgens E. CD40 in coronary artery disease: a matter of macrophages? Basic Res. Cardiol., 2016, Vol. 111, no. 4, p. 38.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kyaw T., Peter K., Li Y., Tipping P., Toh B.H., Bobik A. Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges. Br. J. Pharmacol., 2017, Vol. 174, no. 22, pp. 3956-3972.</mixed-citation><mixed-citation xml:lang="en">Kyaw T., Peter K., Li Y., Tipping P., Toh B.H., Bobik A. Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges. Br. J. Pharmacol., 2017, Vol. 174, no. 22, pp. 3956-3972.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Li.Q, Wang Y., WangYi., Zhou Q., Chen K., Wang Y.M., Wei W, Wang Y. Distinct different sensitivity of Treg and Th17 cells to Fas-mediated apoptosis signaling in patients with acute coronary syndrome. Int. J. Clin. Exp. Pathol, 2013, Vol. 6, no. 2, pp. 297-307.</mixed-citation><mixed-citation xml:lang="en">Li.Q, Wang Y., WangYi., Zhou Q., Chen K., Wang Y.M., Wei W, Wang Y. Distinct different sensitivity of Treg and Th17 cells to Fas-mediated apoptosis signaling in patients with acute coronary syndrome. Int. J. Clin. Exp. Pathol, 2013, Vol. 6, no. 2, pp. 297-307.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rahmati Z., Amirzargar A.A., Saadati S., Rahmani F., Mahmoudi M.J., Rahnemoon Z., Eskandari V, Gorzin F., Hedayat M., Rezaei N. Association of levels of interleukin 17 and T-helper 17 count with symptom severity and etiology of chronic heart failure: a case-control study. Croat. Med. J., 2018, Vol. 59, no. 4, pp. 139-148.</mixed-citation><mixed-citation xml:lang="en">Rahmati Z., Amirzargar A.A., Saadati S., Rahmani F., Mahmoudi M.J., Rahnemoon Z., Eskandari V, Gorzin F., Hedayat M., Rezaei N. Association of levels of interleukin 17 and T-helper 17 count with symptom severity and etiology of chronic heart failure: a case-control study. Croat. Med. J., 2018, Vol. 59, no. 4, pp. 139-148.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sahinarslan A., Boyaci B., Kocaman S.A., Topal S., Ercin U., Okyay K., Bukan N., Yal^n R., Cengel A. The relationship of serum soluble fas ligand (sFasL) level with the extent of coronary artery disease. Int. J. Angiol., 2012, Vol. 21, no. 1, pp. 29-34.</mixed-citation><mixed-citation xml:lang="en">Sahinarslan A., Boyaci B., Kocaman S.A., Topal S., Ercin U., Okyay K., Bukan N., Yal^n R., Cengel A. The relationship of serum soluble fas ligand (sFasL) level with the extent of coronary artery disease. Int. J. Angiol., 2012, Vol. 21, no. 1, pp. 29-34.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Walter T., Suselbeck T., Borggrefe M., Swoboda S., Hoffmeister H.M., Dempfle C.E. Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. In Vivo, 2010, Vol. 24, no. 2, pp. 189-193.</mixed-citation><mixed-citation xml:lang="en">Walter T., Suselbeck T., Borggrefe M., Swoboda S., Hoffmeister H.M., Dempfle C.E. Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. In Vivo, 2010, Vol. 24, no. 2, pp. 189-193.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
